[
    [
        {
            "time": "2018-04-25",
            "original_text": "Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication",
            "features": {
                "keywords": [
                    "MRK",
                    "PFE",
                    "FDA",
                    "Kymriah",
                    "Indication"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-27",
            "original_text": "Aduro (ADRO) Q1 Loss Narrower Than Expected, Revenues Beat",
            "features": {
                "keywords": [
                    "ADRO",
                    "Q1",
                    "Loss",
                    "Narrower",
                    "Revenues",
                    "Beat"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-05-03",
            "original_text": "FDA approves Novartis combo therapy for aggressive type of thyroid cancer",
            "features": {
                "keywords": [
                    "FDA",
                    "Novartis",
                    "combo",
                    "therapy",
                    "thyroid",
                    "cancer"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-04",
            "original_text": "Prolia Revenue Grew 16% in 1Q18",
            "features": {
                "keywords": [
                    "Prolia",
                    "Revenue",
                    "Grew",
                    "16%",
                    "1Q18"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "3 “High Yield Leaders” to Buy for 5% to 12% Payouts",
            "features": {
                "keywords": [
                    "High",
                    "Yield",
                    "Leaders",
                    "Buy",
                    "Payouts"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "dividend stocks"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-05-15",
            "original_text": "Kyprolis Is Expected to Boost Amgen’s Revenue Growth",
            "features": {
                "keywords": [
                    "Kyprolis",
                    "Amgen",
                    "Revenue",
                    "Growth"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-06-01",
            "original_text": "The Swiss Stock Market",
            "features": {
                "keywords": [
                    "Swiss",
                    "Stock",
                    "Market"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general market"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 4,
                "Source_Recency": 5
            }
        }
    ]
]